Processa Pharmaceuticals ... (PCSA)
NASDAQ: PCSA
· Real-Time Price · USD
0.33
0.03 (9.78%)
At close: Jun 09, 2025, 3:59 PM
Processa Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -9.12M | -11.85M | -11.53M | -10.22M | -9.83M | -11.12M | -21.73M | -25.67M | -28.22M | -27.42M | -17.6M | -14.56M | -12.56M | -11.43M | -17.98M | -18.06M | -15.64M |
Depreciation & Amortization | 643.00 | 782.00 | 621.00 | 500.00 | 20.54K | 40.2K | 237.19K | 434.23K | 611.17K | 788.5K | 788.5K | 787.07K | 788.78K | 790.97K | 794.79K | 800.03K | 802.15K |
Stock-Based Compensation | 461.87K | 629.51K | 731.28K | 719.99K | 886.48K | 1.06M | 3.58M | 6.65M | 8.34M | 8.83M | 7.2M | 5.07M | 3.93M | 3.41M | 4.63M | 3.71M | 2.94M |
Other Working Capital | -1.03M | -681.67K | -777.84K | -574.7K | 719.07K | 621.14K | 782.99K | 646.66K | 360.23K | 388.89K | -405.15K | -130.52K | -362.43K | -1.08M | -1.44M | -1.35M | -942.85K |
Other Non-Cash Items | -279K | -233.45K | 56.82K | 55.36K | 399.05K | 1.68M | 8.7M | 8.73M | 8.96M | 7.66M | 354.99K | 317.96K | 225.83K | 220.61K | 6.86M | 9.01M | 8.88M |
Deferred Income Tax | n/a | n/a | -291.78K | -291.78K | -311.96K | -331.76K | -39.98K | -39.98K | -19.8K | n/a | -181.75K | -304.19K | -441.36K | -530.61K | -1.06M | -1.01M | -962.14K |
Change in Working Capital | -600.75K | -112.4K | -412.43K | 139.36K | 857.73K | 605.21K | 818.23K | 237.58K | 406.92K | 543.6K | -402.99K | 275.78K | -223.36K | -1.18M | -1.51M | -1.13M | -859.04K |
Operating Cash Flow | -9.2M | -11.25M | -11.12M | -9.28M | -8M | -8.06M | -8.44M | -9.65M | -9.92M | -9.61M | -9.83M | -8.41M | -8.28M | -8.72M | -8.27M | -6.68M | -4.84M |
Capital Expenditures | -3.24K | -3.24K | -3.24K | -2.78K | -2.78K | -2.78K | -2.78K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -3.24K | -3.24K | -3.24K | -2.78K | -2.78K | -2.78K | -2.78K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | -4.31K | -5.2K | -3.74K | -2.3K | -895 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 200K | 200K |
Common Stock Repurchased | -5.98K | -15.9K | 37.16K | -11.93K | -9.92K | n/a | -106.34K | -88.84K | -88.84K | -388.84K | -371.66K | -364.4K | -364.4K | -64.4K | -28.08K | -95.21 | -95.21 |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 4.44M | -8.87K | -61.31K | -61.31K | -61.31K | -52.75K | n/a | -35.25K | -35.25K | -35.25K | -41.45K | -163.41K | -186.49K | -186.49K | 17.19M | 16.99M | 17.67M |
Financial Cash Flow | 5.91M | 7.73M | 7.16M | 6.18M | 6.18M | 6.27M | 6.25M | 6.26M | 6.26M | -388.84K | -203.88K | -353.82K | -376.9K | 9.8M | 27.03M | 27.06M | 27.75M |
Net Cash Flow | -6.02M | -3.51M | -3.97M | -3.11M | -1.82M | -1.8M | -2.19M | -3.39M | -3.65M | -9.99M | -10.04M | -8.77M | -8.65M | 1.08M | 18.77M | 20.38M | 22.91M |
Free Cash Flow | -9.2M | -11.25M | -11.12M | -9.28M | -8M | -8.07M | -8.44M | -9.65M | -9.92M | -9.61M | -9.83M | -8.41M | -8.28M | -8.72M | -8.27M | -6.68M | -4.84M |